Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
choline C 11
- Development stage
- Approved
- Lead developer
- Mayo Clinic
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
Choline C 11 is a radiopharmaceutical diagnostic agent used in positron emission tomography (PET) imaging to detect and evaluate prostate cancer. As a radiolabeled analog of the essential nutrient choline, it is taken up by cells via choline transporters and subsequently phosphorylated by choline kinase into phosphocholine, which is then incorporated into cell membranes as phosphatidylcholine. Because malignant prostate cells exhibit significantly increased rates of proliferation and membrane synthesis, they demonstrate higher uptake and retention of the tracer compared to normal tissues. This allows for the identification of primary tumors and metastatic spread to lymph nodes and bone. Wake Forest University Health Sciences has specifically studied Choline C 11 PET-CT as a tool for the metastatic evaluation of patients with newly diagnosed high-risk adenocarcinoma of the prostate.
- Brand names
- Choline C 11
- Other names
- [11C]cholineCarbon-11 cholineCarbon11 cholineCarbon 11 choline11C-labeled choline
02
Targets
CHKA (Choline kinase)CHT1 (High-affinity choline transporter 1)
Beyond the preview
Go deeper on choline C 11.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on choline C 11.